China Healthwise Holdings Limited announced earnings guidance for the six months ended 30 June 2023. For the six months ended 30 June 2023 ("HY2023"), the Group expects to record a loss attributable to equity holders within a range of approximately HKD 29 million to HKD 33 million of the Company as compared to a loss attributable to equity holders of the Company of approximately HKD 15 million for the six months ended 30 June 2022 ("HY2022"). The expected increase in loss is mainly due to increase in the impairment loss in respect of loan receivables from approximately HKD 3 million in HY2022 to approximately HKD 28 million in HY2023.